Please check back later this morning. Serologicals, which produces human antibody products, proteins and tissue culture media, also said its guidance remains unchanged for 10 percent to 15 percent growth in full-year revenue and a slightly higher percentage gain for earnings per share compared with pro forma amounts in 2000. Pro forma results exclude operations of the company's Seramed unit, which was sold in August 2000. 2 cents Parentheses indicate loss. Parentheses indicate loss.
Parentheses indicate loss.
From continuing operations.